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Abstract
Background: Nutrition is one of the fundamentals of care provided to critically ill adults. The volume of enteral
nutrition received, however, is often much less than prescribed due to multiple functional and process issues. To
deliver the prescribed volume and correct the energy deficit associated with enteral nutrition alone, parenteral
nutrition can be used in combination (termed “supplemental parenteral nutrition”), but benefits of this method
have not been firmly established. A multi-centre, randomised, clinical trial is currently underway to determine if
prescribed energy requirements can be provided to critically ill patients by using a supplemental parenteral
nutrition strategy in the critically ill.
Methods/design: This prospective, multi-centre, randomised, stratified, parallel-group, controlled, phase II trial aims
to determine whether a supplemental parenteral nutrition strategy will reliably and safely increase energy intake
when compared to usual care. The study will be conducted for 100 critically ill adults with at least one organ
system failure and evidence of insufficient enteral intake from six intensive care units in Australia and New Zealand.
Enrolled patients will be allocated to either a supplemental parenteral nutrition strategy for 7 days post
randomisation or to usual care with enteral nutrition. The primary outcome will be the average energy amount
delivered from nutrition therapy over the first 7 days of the study period. Secondary outcomes include protein
delivery for 7 days post randomisation; total energy and protein delivery, antibiotic use and organ failure rates (up
to 28 days); duration of ventilation, length of intensive care unit and hospital stay. At both intensive care unit and
hospital discharge strength and health-related quality of life assessments will be undertaken. Study participants will
be followed up for health-related quality of life, resource utilisation and survival at 90 and 180 days post
randomisation (unless death occurs first).
Discussion: This trial aims to determine if provision of a supplemental parenteral nutrition strategy to critically ill
adults will increase energy intake compared to usual care in Australia and New Zealand. Trial outcomes will guide
development of a subsequent larger randomised controlled trial.
Trial registration: NCT01847534 (First registered 5 February 2013, last updated 14 October 2015)
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controlled trials
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Background
In critical illness, enteral nutrition (EN) is usually deliv-
ered to provide estimated daily nutrition requirements
via a gastric tube [1–3]. EN is the preferred choice of
nutrition for critically ill adults because it mimics nor-
mal nutritional intake in health, preserves gastrointes-
tinal tract (GIT) function, is relatively inexpensive and
has been associated with a reduced incidence of pneu-
monia and mortality when started early after intensive
care unit (ICU) admission [4–6]. The alternative to EN
is parenteral nutrition (PN), which is a specialised solu-
tion designed to provide daily nutrition requirements
intravenously. PN is used when a patient does not have
a functioning GIT or when a clinical preference for use
of PN exists [1, 7]. Until recently it was thought that PN
was associated with an increased risk of infectious com-
plications and mortality, although new data indicates
that these risks may have reduced with contemporary
care in the ICU [8, 9].
It has been reported that only 45–60 % [10] of energy
is provided when EN is used alone due to delivery and
tolerance problems [11], resulting in failure to meet daily
energy requirements with unknown consequences. The
strategy of “supplemental PN” aims to correct the energy
deficit from inadequately delivered EN with a supply of
PN, to meet 100 % of daily energy requirements in com-
bination. This approach is based on the premise that de-
livery of close to 100 % of estimated daily nutrition
requirements may improve patient outcomes. Whilst the
strategy has been demonstrated to deliver close to 100 %
of estimated energy needs, the effects on clinical out-
comes have been contradictory [12–14]. A prospective
randomised control trial (RCT) which investigated sup-
plemental PN initiated early (within 48 hours of ICU ad-
mission) versus late (8 days after ICU admission)
demonstrated that late supplemental PN resulted in pa-
tients being more likely to be discharged earlier from the
ICU, with fewer infections when compared to patients in
the early arm. However, late supplemental PN led to a
higher proportion of hypoglycaemia, a more pronounced
inflammatory response and did not affect overall hos-
pital, 90-day mortality or functional status [15]. The out-
comes from this study appear to be contradictory and
may relate to the use of aggressive insulin therapy, which
is not practiced in Australia and New Zealand (ANZ)
[16]. Furthermore, the population in this RCT were
largely patients undergoing cardiac surgery, and of low
to moderate acuity. This patient group can usually re-
turn to volitional oral intake quickly and do not often
require artificial nutrition due to their short duration of
ICU stay; thus, it would seem there may be a low likeli-
hood of benefit from supplemental PN in this popula-
tion. Another RCT investigating supplemental PN from
admission to ICU versus usual care found that the
supplemental PN group received more energy (28 kcal/
kg per day versus 20 kcal/kg per day) and had fewer
nosocomial infections compared with the usual care
group (27 % versus 38 %, respectively), but only on days
9–28 of ICU admission [14]. This finding may be ex-
plained by the positive effect of adequately delivered nu-
trition on immunity later in the ICU stay, which is also a
biologically plausible explanation.
Thus, it seems that supplemental PN in addition to
standard EN may be able to deliver increased energy to
critically ill adults, but the exact clinical effects and the
population that may benefit most remain undefined.
Our aim is to determine if a supplemental PN strategy
commenced 48–72 hours following ICU admission will
deliver increased amounts of energy to adults with se-
vere critical illness, when compared with usual care in
six ANZ tertiary ICUs.
Methods
Design and study participants
A stratified, prospective, multi-centre, unblinded, rando-
mised, parallel-group phase II study will be undertaken.
Inclusion criteria
1) Admitted to intensive care between 48 hours and
72 hours previously
2) Mechanically ventilated at the time of enrolment
and expected to remain ventilated until the day after
tomorrow
3) At least 16 years of age
4) Have central venous access suitable for PN solution
administration
5) Have one or more organ system failure related to
their acute illness defined as:
a) PaO2/FiO2 ≤ 300 mmHg
b) Currently on one or more continuous vasopressor
infusions which were started at least 4 hours ago at
a minimum dose of:
 Dopamine ≥ 5 mcg/kg/min
 Noradrenaline ≥ 0.1 mcg/kg/min
 Adrenaline ≥ 0.1 mcg/kg/min
 Any dose of vasopressin
 Milrinone > 0.25 mcg/kg/min)
6) Renal dysfunction defined as
In patients without known renal disease:
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a) Serum creatinine > 171 mmol/L OR
b) Currently receiving renal replacement therapy
In patients with known renal disease:
a) An absolute increase of > 50 % in serum creatinine
from baseline OR
b) Currently receiving renal replacement therapy
7) Currently has an intracranial pressure monitor or
ventricular drain in situ
8) Currently receiving extracorporeal membrane
oxygenation
9) Currently has a ventricular assist device.
Exclusion criteria
Patients will be excluded if:
1) Both EN and PN cannot be delivered at enrolment
(that is, either an enteral tube or a central venous
catheter cannot be placed or clinicians feel that EN
or PN cannot be safely administered due to any
other reason)
2) Currently receiving PN
3) Standard PN solutions cannot be delivered at
enrolment (that is, clinicians believe that a patient
definitely needs a specific parenteral nutrition
formulation (for example, glutamine
supplementation or specific lipid formulation)
4) Death is imminent or deemed highly likely in the
next 96 hours
5) There is a current treatment limitation in place or
the patient is unlikely to survive to 6 months due to
underlying illness
6) More than 80 % of energy requirements have been
satisfactorily delivered via the enteral route in the
last 24 hours
7) Are known to be pregnant
8) The treating clinician does not believe the study to
be in the best interest of the patient.
Randomisation, allocation concealment and blinding
Concealed randomisation will be performed via a web-
based system which includes randomisation in blocks of
6 at each site. Treatment allocation will be stratified by
site. The trial is unblinded.
Trial intervention and comparator
The intervention is the delivery of a supplemental PN
strategy using Olimel N9-840E/Triomel 9, manufactured
and supplied by Baxter Healthcare Corporation, Old
Toongabbie NSW 2146, Australia. A multi-trace element
solution (10 ml), multi-vitamin (Cernevit, Baxter
Healthcare Corporation, 5 ml) and ascorbate (300 milli-
grams) for stability will be added to the intervention in a
Baxter Healthcare Corporation compounding centre fol-
lowing good manufacturing practice.
Further details on the interventional product can be
viewed at Additional file 1.
The comparator arm will be usual care, with provision
and management of nutrition as per local practice at
each participating site.
The intervention period is defined as 7 days from the
day of randomisation.
Study procedures common to both arms
Patients will be screened for eligibility by research coor-
dinators/medical staff at each site when they are be-
tween 48 and 72 hours of their first admission to the
ICU. Those that are found to meet all the inclusion and
none of the exclusion criteria will be randomised using a
web-based randomisation system.
At randomisation, the body weight of study partici-
pants will be standardised using calculated body
weight (CBW). To determine CBW, actual or esti-
mated weight and height will be required to allow
calculation of body mass index (BMI). The weight
used to determine BMI will be defined according to
the following hierarchy:
a) Actual body weight if it has been recorded in the
previous 6 weeks
b) Estimated dry weight if actual weight is not known.
Height will be estimated using demi arm span [17].
CBW will be the patient’s actual weight if their BMI is
deemed to be <25 kg/m2. If their BMI is ≥25 kg/m2, the
CBW will be set to the patient’s ideal weight at a BMI of
23 kg/m2. Once the CBW has been determined, it will
not be changed for the study duration.
Daily energy requirements will be estimated using
CBW with a fixed prescription. The daily energy require-
ments will be set at 25 kcal/kg CBW unless the patient
is receiving renal replacement therapy (RRT) and/or
extracorporeal membrane therapy (ECMO), where
30 kcal/kg of CBW will be used. The daily energy re-
quirement will only be changed during the study period
if the patient commences or discontinues ECMO and/or
RRT (with the two requirement options being 30 kcal/kg
CBW or 25 kcal/kg CBW, respectively). A higher energy
requirement has been chosen during RRT and/or ECMO
due to the potential for increased metabolic stress and
inflammation associated with the delivery of both ther-
apies and the underlying disease processes that require
these treatments [18]. Once randomised, the target rate
for continuous EN delivery will be calculated by the
treating clinical team to match the daily energy
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requirement, with the assumption that all patients
should receive 100 % of their daily energy requirements
from administration of EN and rounded up to the near-
est 5 ml/hour. The choice of EN formula, protein re-
quirement estimation and management of blood glucose
levels will be according to local protocols.
Figure 1 demonstrates the study processes from
screening to study completion.
Study procedures in the intervention arm
Day of randomisation:
The interventional product will be administered to
intervention patients within 2 hours of randomisation
via a central venous catheter (including long-term
central catheters, for example, a Hickman catheter if
already in situ) or a peripherally inserted central cath-
eter. Management of the line will be as per the partici-
pating hospital’s usual procedure. Due to the increased
risk of overfeeding with energy when PN is used, the
intervention strategy has been designed to minimise
this risk. Thus, the maximum amount of energy pro-
vided by the intervention will be 20 kcal/kg/day (or
24 kcal/kg/day for those on RRT and/or ECMO), which
equals 80 % of the daily energy requirement set at
25 or 30 kcal/kg/day, respectively. This will allow for
small amounts of energy provided by EN, 25/50 %
glucose and propofol (non-nutritional energy
sources) in addition to interventional product in the
intervention arm.
Fig. 1 Study overview. CRP: C-reactive protein; EN: enteral nutrition; EQ-5D: EuroQuol 5 dimension; ICU: intensive care unit; LFTs: liver function
tests; LOS: length of stay; MV: mechanical ventilation; PN: parenteral nutrition; 6MWT: 6-minute walk test
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The starting rate of PN will be determined by the
amount of energy received via the enteral route in the
24 hours prior to randomisation:
a) Between 40–80 % of daily energy requirement
received from EN: PN rate will equal delivery of
10 kcal/kg of CBW/day (or 12 kcal/kg of CBW/day
for those on RRT and/or ECMO)
b) Less than 40 % of daily energy requirement received
from EN: PN rate will equal delivery of 20 kcal/kg of
CBW/day (or 24 kcal/kg of CBW/day for those on
RRT and/or ECMO).
Management of EN in the intervention arm will be
according to unit protocol. Every attempt will be
made by the treating clinical team to achieve delivery
of EN in the intervention arm to provide 100 % of
daily energy requirements. Importantly, EN must not
be reduced based on the amount of intervention be-
ing administered.
Daily review of intervention:
From study day 2 until study day 7 (or ICU discharge,
whichever occurs first), the adequacy of energy from
EN and non-nutritional sources will be assessed at
bkmidday by a member of the site research team. Total
energy intake will be determined for the 24 hours prior
to review and used to determine the rate of delivery
bkof study PN for the subsequent 24 hours (Fig. 2).
Once the rate is set for the following 24 hours by the
research team, it should not be altered by the treating
team unless deemed necessary for patient safety.
Fig. 2 Daily adjustment of PN rate in intervention arm. ECMO: extracorporeal membrane oxygenation; EN: enteral nutrition; PN: parenteral
nutrition; RRT: renal replacement therapy
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Management of interruptions to EN in the interven-
tion arm:
In the event of an anticipated or actual interruption to
EN for a period of 2 hours or more in the intervention
arm, the interventional strategy will be adjusted to
minimise energy deficit for the period of the
interruption. During the interruption period, the
intervention will be run at the hourly rate
corresponding to 20 kcal/kg or 24 kcal/kg for those on
RRT and/or ECMO. If the patient is already receiving
the highest rate of the intervention, there will be no
change to the rate during the interruption period. As
soon as is practical, EN should be recommenced as per
local protocol and the intervention returned to the rate
determined as per the midday assessment.
Cessation of study intervention prior to the end of the
study period:
The intervention will cease either prior to ICU
discharge or 7 days following enrolment if energy from
EN and non-nutritional sources provides more than
80 % of estimated energy requirements on any day.
Cessation on any one day will not preclude recom-
mencement in the following 24 hours should the strat-
egy be indicated based on the procedures previously
outlined, until study day 7.
Should a patient commence oral intake during the 7-
day study period, the intervention will cease when it is
deemed that the patient will resume oral intake with
the intent to provide nutrition, that is, not only to pro-
vide water or fluid intake.
Usual care arm
After enrolment, patients allocated to the usual care arm
will commence or continue EN via an enteral tube to a
target rate aimed to provide 100 % of daily energy require-
ments. All other aspects of nutrition therapy will be man-
aged according to local unit protocol and, if required,
include the use of promotility agents and the placement of
nasojejunal feeding tubes prior to commencement of PN.
PN will only be used in the usual care arm if the above
methods have been attempted, or if an absolute contra-
indication to EN develops. The interventional product will
be used in the usual care arm should PN be required
within 7 days of randomisation. If PN is required after
study day 7, it will be the usual hospital PN formula, man-
aged by the treating clinicians as clinically appropriate.
Outcome measures
The primary outcome of this trial is the mean energy
amount in calories delivered from nutrition therapy over
the first 7 days of the study period.
Secondary outcomes include:
1) Total protein amount delivered in the first 7 days of
the study period
2) Total energy amount delivered in the ICU stay (up
to 28 days)
3) Total protein amount delivered in the ICU stay (up
to 28 days)
4) Total antibiotic usage
5) Sequential Organ Failure Assessment scores
6) Duration of mechanical ventilation
7) Duration of ICU and hospital stay
8) Mortality to 180 days post randomisation
9) Functional and quality of life to 180 days post
randomisation
Study management and data collection
This trial will be coordinated by the Australian and New
Zealand Intensive Care Research Centre (ANZIC-RC),
Monash University, Melbourne, Australia. Dedicated
study tools will be provided to participating sites to
standardise all study procedures. Data will be collected
at each site by dedicated and trained research staff using
a paper case report form. Study variables collected will
include baseline demographics such as anthropometric
measurements, admission diagnoses, physiological pa-
rameters, Acute Physiology and Chromic Health Evalu-
ation II, daily information including nutrition therapy,
antibiotic use, blood tests and outcome data such as
mortality, protocol deviations and serious adverse events
(SAEs). At ICU and hospital discharge, functional,
strength and health-related quality of life (HRQOL) as-
sessments will be undertaken using the 6-minute walk
test if possible and/or the highest level of function scale
[19], hand grip strength and the EuroQol 5 dimension 5
level (EQ-5D-5 L) tools, respectively. Study participants
will be contacted at 90 and 180 days post randomisation
(unless previously deceased) to assess HRQOL, resource
utilisation and survival. Follow-up assessments will be
conducted via telephone by the research staff at the ran-
domising site using a pre-prepared script to obtain the
assessment using the EQ-5D-5 L. In the event that the
patient is unable to complete the assessment at any time
point, a relative or friend for the patient will be used as
per the instructions for the EQ-5D-5 L. Data will be en-
tered by the research staff at each participating site into
a web-based database developed by Spiral Web Solu-
tions, Wellington, New Zealand. Table 1 details the full
table of events from baseline to outcome assessment.
Ethical considerations
The study protocol has been approved by The Alfred
Hospital Ethics Committee in Australia and the Multi-
Region Ethics Committee in New Zealand.
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Participants in this trial will be unable to provide in-
formed consent for themselves to participate in the
study at the time of enrolment. A delayed consent model
has been approved by the responsible ethics committees,
which means a patient’s legal surrogate, relative/friend
or whanau member will be approached for consent to
participate in the study. Following consent from a pa-
tient’s legal surrogate, relative/friend or whanau member,
the patient will be approached to give consent to con-
tinue in the trial if they recover the ability to do so and
the timing is appropriate.
Sample size and power
Using two published RCTs on nutrition therapy in ANZ
critically ill patients, we estimated that the usual care
group would receive an average of 1,400 kcal/day. We
aim to deliver an additional 420 kcal/day (using a stand-
ard deviation of 600 kcal/day) to the intervention group,
which is a 30 % relative increase in energy delivery and
requires a sample size of 100 patients (80 % power, sig-
nificance 0.05).
This sample size will also provide baseline rates of
other key secondary outcomes which could be used in
the future to inform sample size estimations for larger
RCTs assessing clinical outcomes.
Statistical analysis plan
Statisticians at the Australian and New Zealand Inten-
sive Care Research Centre (ANZIC-RC) will perform
statistical analysis using the intention-to-treat principle.
All data will initially be assessed for normality and will
be log-transformed as appropriate. Baseline variables
and single measure outcomes will be compared using
chi-square tests for equal proportion (or Fisher’s exact
tests if numbers are small), Student’s t-test for normally
distributed outcomes and Wilcoxon rank-sum tests
otherwise. Continuously normally distributed repeated
measure outcomes will be compared between groups
using longitudinal mixed modelling fitting main effects
Table 1 Table of events: usual care and intervention arms












Apache II score X
Apache III diagnosis X
Daily dataa (ICU) X X X X X X X X X X X X X X X X X
LFTs, WBC X x x x x x x X x x x x x x X X X
Use of new antibiotics X X X X X X X X X X X X X X X X X
SOFA score X X X X X X X X
TG X X X X




Survival status X X X X
Mid-upper arm
muscle circumference
X Measured once patient is
ready for ICU D/C
X
Hand grip Measured once patient is
ready for ICU D/C
X
6-minute walk test X
QOL X X X
X denotes must be collected on specified day
x denotes collect only if measured, no need to specially collect
Abbreviations used in table: CRP C-reactive protein, EN enteral nutrition, ICU intensive care unit, LOS length of stay, MV mechanical ventilation, PN parenteral nutrition,
QOL quality of life, SOFA Sequential Organ Failure Assessment, TG triglycerides
aDaily data: The following variables will be collected daily: target energy and protein requirements, received energy and protein amounts, received EN and PN
volumes, AM BGL levels, units of insulin delivered, gastric residual volumes, documented episodes of vomiting, documented episode of abdominal distension,
documented episode of witnessed aspiration
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for treatment and time with an interaction between
treatment and time to determine if groups behave differ-
ently over time. Sensitivity analysis accounting for site,
known covariates and baseline imbalances will also be
performed for all outcomes, using logistic regression for
binomial outcomes and mixed linear or non-linear mod-
elling for continuous outcomes. Analysis will be per-
formed using SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA), and a two-sided p-value of 0.05 will be con-
sidered statistically significant.
Data and safety monitoring
Given the size of the trial, there are no planned interim
analyses, and there is no dedicated data safety monitoring
board. Safety will be monitored by reported adverse events
and SAEs and reviewed by the study management com-
mittee (listed in Appendix 1) and Baxter Healthcare Cor-
poration. All study sites will have an initial monitoring
visit conducted by the project manager after two to five
patients have been recruited. At this site visit, one inter-
vention and one usual care arm patient will have 100 %
source data verification at this visit; all other patients
monitored at the visit will have consent procedures and
eligibility criteria checked. Furthermore, intervention pa-
tients monitored at this initial visit will also have interven-
tion delivery reviewed for adherence to the study protocol.
Additional monitoring visits will be completed based on
recruitment rates per site and any identified issues which
need review after the initial monitoring visit.
The project manager will conduct remote monitoring
of data completeness via the study website, and any data
queries will be sent to the site for review.
Discussion
Nutrition is a commonly used therapy in the ICU. It is
relatively inexpensive compared to other treatments and,
if used correctly, may positively affect clinical and func-
tional outcomes, although this remains to be definitively
determined. Large-scale RCTs to date have failed to de-
liver EN to meet estimated energy requirements, or have
delivered nutrition in a population or manner that
makes the evidence difficult to translate into clinical
practice. This study aims to determine if a supplemental
PN strategy will safely deliver close to 100 % of energy
requirements compared to usual care, identify a patient
population who may benefit most and minimise the risks
of overfeeding. This information will assist in the devel-
opment of future studies to provide definitive answers
on the role of energy intake in critical illness.
Trial status
The trial commenced recruitment on 17 February 2014.
Final recruitment is expected to be achieved in late 2015
with 6 month outcomes available by early 2016.
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Management committee of the Supplemental Parenteral
Nutrition in Critically Ill Patients Phase II Randomised
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Shay McGuinness, Emma Ridley, Andrew Davies,
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